Literature DB >> 1466398

Immunohistochemical analysis of p53 expression in malignant lymphomas.

J W Said1, R Barrera, I P Shintaku, H Nakamura, H P Koeffler.   

Abstract

p53 is a tumor suppressor gene that commonly undergoes mutations in human tumors, including lymphomas. Because p53 mutations are not restricted to a single locus, immunohistochemistry is useful to detect p53 expression and correlate this finding with lymphoma phenotype. Cryostat sections from 125 cases of lymphoma were analyzed for p53 expression using three different monoclonal antibodies (pAb 421, 1801, 240) which react with human cellular p53 and a common conformational epitope on mutant p53. A control antibody (pAb 246) reacts only with wild type p53 of murine origin and was negative in all cases. Tissue from 29 cases of lymphoid hyperplasia, including six from human immunodeficiency virus-positive (HIV+) patients, were negative for p53. p53 was predominantly localized in nuclei of high-grade lymphomas, including 14 of 46 cases of B cell immunoblastic lymphomas and two of five T cell immunoblastic lymphomas. p53 expression was relatively common in lymphomas from HIV+ patients, and unusual in intermediate and low-grade lymphomas of follicular center cell type. Low-grade lymphoma of small lymphocytic type disclosed p53+ large cells (paraimmunoblasts) that may play a role in tumor progression in this lymphoma subtype. p53 was also strongly expressed in the nuclei of Reed Sternberg cells from 19 of 37 cases of Hodgkin's disease, including six cases of mixed cellularity, and 13 cases of nodular sclerosing type. Immunohistochemical staining is a rapid method to identify p53 expression in lymphomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1466398      PMCID: PMC1886771     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  22 in total

1.  Ki-1-positive large cell lymphomas, a heterogenous group of neoplasms. Morphologic, immunophenotypic, genotypic, and clinical features of 24 cases.

Authors:  R J Penny; J C Blaustein; J A Longtine; G S Pinkus
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

Review 2.  B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL.

Authors:  G Dighiero; P Travade; S Chevret; P Fenaux; C Chastang; J L Binet
Journal:  Blood       Date:  1991-10-15       Impact factor: 22.113

3.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Authors:  G Gaidano; P Ballerini; J Z Gong; G Inghirami; A Neri; E W Newcomb; I T Magrath; D M Knowles; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

4.  Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas.

Authors:  C Doglioni; P Pelosio; A Mombello; A Scarpa; M Chilosi
Journal:  Hematol Pathol       Date:  1991

5.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.

Authors:  W Maltzman; L Czyzyk
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

6.  Paraimmunoblastic variant of small lymphocytic lymphoma/leukemia.

Authors:  W C Pugh; J T Manning; J J Butler
Journal:  Am J Surg Pathol       Date:  1988-12       Impact factor: 6.394

7.  Chronic lymphocytic leukemia with coexistent Hodgkin's disease. Implications for the origin of the Reed-Sternberg cell.

Authors:  J Williams; A Schned; J D Cotelingam; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1991-01       Impact factor: 6.394

8.  Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells.

Authors:  C Schmid; L Pan; T Diss; P G Isaacson
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

9.  Immunocytochemical detection of p53 in human gliomas.

Authors:  J M Bruner; H Saya; R P Moser
Journal:  Mod Pathol       Date:  1991-09       Impact factor: 7.842

10.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

Authors:  J V Gannon; R Greaves; R Iggo; D P Lane
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

View more
  7 in total

1.  Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies.

Authors:  P Würl; H Taubert; A Meye; D Berger; C Lautenschläger; H J Holzhausen; H Schmidt; H Kalthoff; F W Rath; H Dralle
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.

Authors:  W Chen; N R Cooper
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

3.  Detection of p53 in inflammatory tissue and lymphocytes using immunohistology and flow cytometry: a critical comment.

Authors:  A Nickels; H Selter; M Pfreundschuh; M Montenarh; B Koch
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

Review 4.  Role of p53 in neurodegenerative diseases.

Authors:  J Robert Chang; Mohammad Ghafouri; Ruma Mukerjee; Asen Bagashev; Tinatin Chabrashvili; Bassel E Sawaya
Journal:  Neurodegener Dis       Date:  2011-10-28       Impact factor: 2.977

5.  Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line.

Authors:  Paweena Chunharojrith; Yuki Nakayama; Xiaobing Jiang; Rachel E Kery; Jun Ma; Cristine S De La Hoz Ulloa; Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2015-08-15       Impact factor: 4.102

6.  Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations.

Authors:  A Y Matsushima; E Cesarman; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

7.  p53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas.

Authors:  P Korkolopoulou; J Oates; C Kittas; J Crocker
Journal:  J Clin Pathol       Date:  1994-01       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.